An Open-label, Flexible-dose, Long-term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizophrenia (S1543002)
Principal Investigator: Steven Dubovsky, MD
Sponsor: Solvay Pharmaceuticals


A Randomized, Parallel Group, Multiple Dose, 6-week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects with Psychosis (A7501021)
Principal Investigator: Steven Dubovsky, MD
Sponsor: Pfizer


A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects with Predominant, Persistent Negative symptoms of Schizophrenia (A7501013)
Principal Investigator: Steven Dubovsky, MD
Sponsor: Pfizer


A Multicenter, Double-blind, Flexible Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine with Olanzapine in Subjects who Completed A7501013 (A7501014)
Principal Investigator: Steven Dubovsky, MD
Sponsor: Pfizer


Six Week, Double-Blind, Placebo-Controlled Phase III Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Flexible Doses of Oral Ziprasidone in Adolescent Subjects with Schizophrenia (A1281134)
Principal Investigator: David Kaye, MD
Sponsor: Pfizer


26-Week Open-label extension study evaluation the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia (A1281135)
Principal Investigator: David Kaye, MD
Sponsor: Pfizer

An open label phase 1 Study Assessing central D2 Receptor occupancy using positron emission tomography (PET) following multiple oral dose administration of CP-903,397 in patients with schizophrenia.
Edward Bednarczyk, DPharm Anselm George, MD  Xiu Di Fan, MD
Pfizer Pharmaceuticals